Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes

NCT07276776 · View on ClinicalTrials.gov ↗

Study Summary

This is a single arm feasibility study to evaluate the Omnipod M System in adults with Type 2 Diabetes with the aim to enroll to 40 participants aged 18-75 years with type 2 diabetes to have a minimum of 20 participants initiate the use of Omnipod M System and the goal of 16 participants completing the 6-week treatment period.

Conditions Studied

Interventions

  • DEVICE Omnipod M system

Study Locations (6)

Massachusetts

  • Joslin Diabetes — Boston
  • MassResearch LLC. — Waltham

Texas

  • Texas Diabetes and Endocrinology (TDE) — Austin
  • Disease & Glandular Disease Clinic — San Antonio

Michigan

  • Henry Ford Health — Detroit

North Carolina

  • Mountain Area Health Educational Center ( MAHEC) — Asheville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-12-12
Est. Completion 2026-02-27
Phase NA

Sponsor

Insulet Corporation

3 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07276776

The ClinicalTrials.gov registry entry for NCT07276776 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insulet Corporation, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention — of which Omnipod M system is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07276776 reports 6 study locations spanning 4 distinct geographic areas — top geographies include Massachusetts, Texas, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07276776 about?

NCT07276776 is a clinical study titled "An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes". This is a single arm feasibility study to evaluate the Omnipod M System in adults with Type 2 Diabetes with the aim to enroll to 40 participants aged 18-75 years with type 2 diabetes to have a minimum of 20 participants initiate the use of Omnipod M System and the goal of 16 participants completing ...

What is the current status of trial NCT07276776?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-12-12. Estimated completion is 2026-02-27.

What conditions does trial NCT07276776 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07276776?

The interventions under investigation include: Omnipod M system (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07276776?

This trial is sponsored by Insulet Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07276776 being conducted?

This trial has 6 study locations across Massachusetts, Michigan, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial